Review anchor
Mitogen-activated protein kinase kinase kinase kinase 4
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Mitogen-activated protein kinase kinase kinase kinase 4
CHEMBL6166
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Mitogen-activated protein kinase kinase kinase kinase 4 as ChEMBL target CHEMBL6166, mapped to UniProt O95819. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL6166
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O95819
Mitogen-activated protein kinase kinase kinase kinase 4
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Mitogen-activated protein kinase kinase kinase kinase 4 matters
Mitogen-activated protein kinase kinase kinase kinase 4 is reviewed as Mitogen-activated protein kinase kinase kinase kinase 4 (UniProt O95819); the current evidence base includes 20 approved drugs, 2659 compounds, and 391 assays, with lead potency reaching pChEMBL 10.1.
Protein context
Mitogen-activated protein kinase kinase kinase kinase 4
Mitogen-activated protein kinase kinase kinase kinase 4 Sequence length is 1239 aa.
Review this target as Mitogen-activated protein kinase kinase kinase kinase 4, mapped to UniProt O95819. Sequence length is 1239 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt O95819
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 20 approved drugs, 2659 compounds, and 391 assays for this target. The dominant activity type is KI. CHEMBL4793665 is the current potency anchor at pChEMBL 10.1.
Use CHEMBL4793665 as the tractability anchor when discussing potency (pChEMBL 10.1).
Activity source · ChEMBL 36 via Core Engine
20 approved
pChEMBL 10.1
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Mitogen-activated protein kinase kinase kinase kinase 4 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt O95819, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
2659
Total Compounds
391
Total Assays
20
Approved Drugs
IC50: 949.0, KI: 1009.0, EC50: 1.0, KD: 379.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4793665
|
10.1 | IC50 | — |
|
|
No preferred name
CHEMBL388978
|
9.5 | IC50 | — |
|
|
No preferred name
CHEMBL3187788
|
9.4 | Ki | — |
|
|
No preferred name
CHEMBL4746566
|
9.4 | IC50 | — |
|
|
No preferred name
CHEMBL4787152
|
9.2 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
PACRITINIB
CHEMBL2035187
|
2022 |
|
|
GILTERITINIB
CHEMBL3301622
|
2018 |
|
|
NERATINIB
CHEMBL180022
|
2017 |
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
PONATINIB
CHEMBL1171837
|
2012 |
|
|
AXITINIB
CHEMBL1289926
|
2012 |
|
|
VANDETANIB
CHEMBL24828
|
2011 |
|
|
PAZOPANIB
CHEMBL477772
|
2009 |
|
|
SUNITINIB
CHEMBL535
|
2006 |
|
|
GEFITINIB
CHEMBL939
|
2003 |
Source Header